Merck & Co., Inc. (MRK) Announces Quarterly Earnings Results

Share on StockTwits

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Thursday, October 25th. The company reported $1.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.05, MarketWatch Earnings reports. Merck & Co., Inc. had a net margin of 8.44% and a return on equity of 34.48%. The firm had revenue of $10.79 billion during the quarter, compared to analyst estimates of $10.87 billion. Merck & Co., Inc. updated its FY 2018 guidance to $4.30-4.36 EPS.

MRK traded up $1.22 during trading on Friday, reaching $76.06. 13,527,455 shares of the company’s stock were exchanged, compared to its average volume of 14,536,856. Merck & Co., Inc. has a 1 year low of $52.83 and a 1 year high of $76.25. The company has a current ratio of 1.44, a quick ratio of 1.15 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $205.07 billion, a PE ratio of 19.11, a P/E/G ratio of 2.07 and a beta of 0.73.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 8th. Shareholders of record on Monday, December 17th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, December 14th. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.48. This represents a $2.20 dividend on an annualized basis and a yield of 2.89%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 48.24%.

MRK has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, October 1st. Credit Suisse Group raised their price target on shares of Merck & Co., Inc. from $71.00 to $81.00 and gave the company an “outperform” rating in a report on Thursday, October 11th. ValuEngine upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Thursday, October 18th. BMO Capital Markets raised their price target on shares of Merck & Co., Inc. from $70.00 to $82.00 and gave the company an “outperform” rating in a report on Monday, October 22nd. Finally, Guggenheim assumed coverage on shares of Merck & Co., Inc. in a report on Monday, October 8th. They issued a “buy” rating on the stock. Four investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Merck & Co., Inc. presently has a consensus rating of “Buy” and a consensus target price of $72.53.

In other news, EVP Julie L. Gerberding sold 36,218 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $75.14, for a total transaction of $2,721,420.52. Following the completion of the transaction, the executive vice president now directly owns 82,481 shares of the company’s stock, valued at approximately $6,197,622.34. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Roger M. Perlmutter sold 225,443 shares of Merck & Co., Inc. stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $75.27, for a total transaction of $16,969,094.61. Following the completion of the sale, the insider now directly owns 366,998 shares in the company, valued at approximately $27,623,939.46. The disclosure for this sale can be found here. Insiders have sold a total of 1,279,104 shares of company stock valued at $92,845,846 over the last three months. 0.32% of the stock is currently owned by insiders.

Merck & Co., Inc. declared that its board has initiated a share repurchase program on Thursday, October 25th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Merck & Co., Inc. (MRK) Announces Quarterly Earnings Results” was first reported by BBNS and is owned by of BBNS. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/11/18/merck-co-inc-mrk-issues-earnings-results/2887311.html.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

See Also: Bull Market

Earnings History for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.